Global Cancer Therapeutics Market Reaches $150 Billion Milestone

NeoGraph Analytics, a leading provider of healthcare market intelligence, today announced the publication of its latest research report on the global cancer therapeutics market, which has reached a landmark $150 billion valuation in 2025. The comprehensive 250-page report analyzes market trends, competitive landscapes, and emerging treatment modalities across solid tumors, hematological cancers, and rare oncology indications. Key findings indicate that immunotherapy and targeted therapies now account for over 60% of oncology drug sales, reflecting a fundamental shift in cancer treatment paradigms. Dr. Sarah Mitchell, Lead Oncology Analyst at NeoGraph Analytics, noted: "The convergence of precision medicine, biomarker-driven patient selection, and combination therapy strategies is driving unprecedented innovation in cancer care. Our research identifies over 800 oncology drugs currently in late-stage clinical development, with breakthrough therapies in cell and gene therapy showing particular promise." The report highlights regional variations in market dynamics, with North America maintaining market leadership while Asia-Pacific emerges as the fastest-growing region due to increasing healthcare expenditure, rising cancer incidence, and expanding access to novel therapeutics. NeoGraph Analytics' cancer therapeutics report is now available for purchase through the company's website, offering detailed competitive intelligence, market forecasts through 2032, and strategic recommendations for pharmaceutical companies, investors, and healthcare organizations.